ImExHS (IME) H1 2026 earnings summary

Executive summary

• AI-native, agentic platform launched and deployed in live hospital environments, with eight proprietary agents operational and major contract wins in Zacatecas, Mexico, and across LATAM.

• Achieved a turnaround to net profit after tax of $66,200 for H1 FY26, compared to a prior loss, with total comprehensive profit of $1,144,516.

• The company operates synergistic cloud-based medical imaging software and radiology services, leveraging internal data for AI development.

• Commercial execution saw large public-sector wins but inconsistent smaller deal flow; partner model validated for software ARR.

• Leadership changes included new CFO, COO, and Company Secretary appointments.

Financial highlights

• H1 FY26 revenue reached $16m (AUD 16m/$15,949,464), up 17% year-over-year (13% in constant currency).

• ARR at 30 June 2026 was $36.8m, up 12% year-over-year; $25m from Radiology, $11.8m from Software.

• Underlying EBITDA was up 311% to $1.3m–$2.0m, with net profit after tax of $66,200.

• Cash balance at 30 June 2026 was $1.27m–$2.0m, with debt reduced to $0.25m.

• Net tangible assets per ordinary security rose to 18.73 cents.

Outlook and guidance

• FY26 revenue guidance is $31.4m–$33.7m, representing 8–16% growth.

• Underlying EBITDA guidance is $2.4m–$2.7m, up 48–66% year-over-year.

• Priorities include converting large-deal capability into repeatable NARR, commencing billing on contracted software, and focusing on collections and working capital.